JP2020531511A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531511A5
JP2020531511A5 JP2020511176A JP2020511176A JP2020531511A5 JP 2020531511 A5 JP2020531511 A5 JP 2020531511A5 JP 2020511176 A JP2020511176 A JP 2020511176A JP 2020511176 A JP2020511176 A JP 2020511176A JP 2020531511 A5 JP2020531511 A5 JP 2020531511A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
patient
eye
micrograms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531511A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048025 external-priority patent/WO2019040919A1/en
Publication of JP2020531511A publication Critical patent/JP2020531511A/ja
Publication of JP2020531511A5 publication Critical patent/JP2020531511A5/ja
Pending legal-status Critical Current

Links

JP2020511176A 2017-08-24 2018-08-24 眼球用医薬組成物 Pending JP2020531511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549872P 2017-08-24 2017-08-24
US62/549,872 2017-08-24
PCT/US2018/048025 WO2019040919A1 (en) 2017-08-24 2018-08-24 OCULAR PHARMACEUTICAL COMPOSITIONS

Publications (2)

Publication Number Publication Date
JP2020531511A JP2020531511A (ja) 2020-11-05
JP2020531511A5 true JP2020531511A5 (https=) 2021-09-30

Family

ID=65439930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511176A Pending JP2020531511A (ja) 2017-08-24 2018-08-24 眼球用医薬組成物

Country Status (8)

Country Link
US (3) US11839616B2 (https=)
EP (1) EP3672598A4 (https=)
JP (1) JP2020531511A (https=)
KR (1) KR20200044873A (https=)
CN (1) CN111629730A (https=)
AU (1) AU2018321926B2 (https=)
CA (1) CA3073718A1 (https=)
WO (1) WO2019040919A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016379444B2 (en) 2015-12-24 2021-04-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
JP2020531511A (ja) 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物
US11957413B2 (en) * 2019-08-06 2024-04-16 University of Pittsburgh—of the Commonwealth System of Higher Education Solitary wave-based trans-lid tonometer
CN115397392A (zh) * 2019-12-05 2022-11-25 Vanda制药公司 眼用药物组合物
JP7826294B2 (ja) * 2020-09-10 2026-03-09 バンダ・ファーマシューティカルズ・インコーポレイテッド Pdeiv媒介性の疾患又は状態を処置する方法
WO2025179141A1 (en) * 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPS62126178A (ja) 1985-11-26 1987-06-08 Mitsubishi Petrochem Co Ltd 新規トリアジン誘導体及びこれを含む除草剤
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
AU5433594A (en) 1992-11-19 1994-06-08 Dainippon Pharmaceutical Co. Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
WO1999038497A2 (en) 1998-01-30 1999-08-05 R-Tech Ueno, Ltd. Ophthalmic composition
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
CA2319554C (en) 1998-03-31 2005-06-28 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
CA2394727A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
RS34004A (sr) 2001-09-21 2006-10-27 Reddy Us Therapeutics Inc. Postupci i sastavi novih triazin jedinjenja
AU2003272740A1 (en) 2002-10-01 2004-04-23 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
AU2004259346A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
BRPI0507278A (pt) 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007095812A1 (en) 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
EP2037924A2 (en) 2006-07-07 2009-03-25 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
US8263607B2 (en) 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
US20120009151A1 (en) 2007-12-21 2012-01-12 Progenics Pharmaceuticals, Inc. Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof
HUE027811T2 (en) 2008-03-05 2016-11-28 Merck Patent Gmbh Quinoxalinone derivatives as stimulators of insulin secretion, methods for their preparation and their use in the treatment of diabetes
WO2010048564A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
FR2958645B1 (fr) 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US8883793B2 (en) 2010-12-29 2014-11-11 Development Center For Biotechnology Tubulin inhibitors and methods of using the same
AU2013365827A1 (en) 2012-12-19 2015-07-09 Novartis Ag Tricyclic compounds as CFTR inhibitors
PT3030568T (pt) 2013-08-08 2018-12-24 Galapagos Nv Tieno[2,3-c]piranos como moduladores de cftr
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP3347912A1 (de) 2015-09-11 2018-07-18 ION-TOF Technologies GmbH Sekundärionen-massenspektrometer und sekundärionen-massenspektrometrisches verfahren
US10035962B2 (en) * 2015-12-21 2018-07-31 Exxonmobil Research And Engineering Company Trim dewaxing of distillate fuel
BR112018012934B1 (pt) 2015-12-24 2023-11-07 The Regents Of The University Of California Reguladores cftr e métodos de uso dos mesmos
RU2742934C2 (ru) 2015-12-24 2021-02-11 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
AU2016379444B2 (en) 2015-12-24 2021-04-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
PL3722291T3 (pl) 2015-12-24 2023-11-27 Respivert Limited Związki indolinonowe i ich zastosowanie w leczeniu chorób zwłóknieniowych
JP2020531511A (ja) 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物

Similar Documents

Publication Publication Date Title
JP2020531511A5 (https=)
Moiseev et al. Penetration enhancers in ocular drug delivery
JP7012075B2 (ja) 眼瞼炎の治療に使用するための医薬組成物
JP7082115B2 (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
CN105307498B (zh) 用于治疗眼病的组合物、制剂和方法
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
NZ785712A (en) Neuroactive steroids, compositions, and uses thereof
RU2017129247A (ru) Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний
JP2018506570A5 (https=)
JP2009530234A5 (https=)
JP2011516477A5 (https=)
Gallagher et al. Development of a poly-ε-lysine contact lens as a drug delivery device for the treatment of fungal keratitis
JP2017520527A5 (https=)
TN2010000251A1 (fr) N-acetyl-dl-leucine medicament neuro et retino protecteur
JP2013534527A5 (https=)
EA201300314A8 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
Cegielska et al. Targeted drug delivery systems for the treatment of glaucoma: Most advanced systems review
WO2016208961A1 (ko) 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
JP6871400B2 (ja) 眼表面疾患の治療のための製剤および関連方法
US9320645B2 (en) Approach to administering ocular medication
JP2018500546A5 (https=)
JP2008540528A5 (https=)
EP4225279A1 (en) Drug containing dissolvable ocular inserts and method of using same
JP2018519299A (ja) 組成物および治療方法
JP2019502719A5 (https=)